BNR Stock Analysis: Brenntag SE | XETRA
Specialty Chemicals | XETRA, Germany | Market Cap: 8.796m EUR | 12M Return: 15.8% | DE000A1DAHH0 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 15.0M
EPS Trend: -82.9%
Qual. Beats: 0
Rev. Trend: -92.2%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Brenntag SE is a German-headquartered global distributor of chemicals and ingredients, operating across Europe, North America, and Asia. Founded in 1874 and based in Essen, the company runs two segments: Brenntag Essentials and Brenntag Specialties, serving end markets such as nutrition, pharma, beauty and personal care, water treatment, coatings, adhesives, polymers, and construction.
Beyond straightforward chemical distribution, Brenntag adds value through services including just-in-time delivery, product mixing and blending, repackaging, inventory management, drum return handling, technical and formulation support, regulatory expertise, and digital sales channels. This service-oriented positioning is typical of specialty chemical distributors, which generate a significant portion of revenue from value-added services such as formulation support and supply chain management rather than from chemical manufacturing itself.
- Brenntag Specialties margin expansion outpaces lower-margin Essentials segment
- Industrial destocking pressures Essentials volumes and pricing in Europe and Americas
- Capital allocation prioritizes debt reduction and targeted M&A in higher-growth verticals
| Net Income: 364.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -1.04 > 1.0 |
| NWC/Revenue: 14.54% < 20% (prev 9.86%; Δ 4.68% < -1%) |
| CFO/TA 0.07 > 3% & CFO 802.8m > Net Income 364.3m |
| Net Debt (3.67b) to EBITDA (1.26b): 2.90 < 3 |
| Current Ratio: 1.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (144.0m) vs 12m ago -0.28% < -2% |
| Gross Margin: 15.69% > 18% (prev 25.04%; Δ -9.36% > 0.5%) |
| Asset Turnover: 134.9% > 50% (prev 148.3%; Δ -13.33% > 0%) |
| Interest Coverage Ratio: 4.84 > 6 (EBIT TTM 763.0m / Interest Expense TTM 157.7m) |
| A: 0.19 (Total Current Assets 5.34b - Total Current Liabilities 3.14b) / Total Assets 11.7b |
| B: 0.31 (Retained Earnings 3.65b / Total Assets 11.7b) |
| C: 0.07 (EBIT TTM 763.0m / Avg Total Assets 11.2b) |
| D: 0.62 (Book Value of Equity 4.43b / Total Liabilities 7.20b) |
| Altman-Z'' = 3.36 = A |
| DSRI: 1.31 (Receivables 3.16b/2.54b, Revenue 15.2b/16.0b) |
| GMI: 1.60 (GM 25.04% / 15.69%) |
| AQI: 0.96 (AQ_t 0.35 / AQ_t-1 0.37) |
| SGI: 0.95 (Revenue 15.2b / 16.0b) |
| TATA: -0.04 (NI 364.3m - CFO 802.8m) / TA 11.7b) |
| Beneish M = -2.29 (Cap -4..+1) = BBB |
As of August 23, 2026, the stock is trading at EUR 60.48 with a total of 432,550 shares traded. Over the past week, the price has changed by -1.47%, over one month by +4.02%, over three months by +4.42% and over the past year by +15.82%.
Current recommended Stop Loss: 58.40 (which is 3.4% or 1.3 ATR below the current price).
Brenntag SE has no consensus analysts rating.
P/E Trailing = 24.1746
P/E Forward = 10.8578
P/S = 0.5804
P/B = 2.0085
P/EG = 1.138
Revenue TTM = 15.2b EUR
EBIT TTM = 763.0m EUR
EBITDA TTM = 1.26b EUR
Long Term Debt = 2.60b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 337.0m EUR (from shortTermDebt, last quarter)
Debt = 4.18b EUR (from shortLongTermDebtTotal, last quarter) + Leases 571.0m
Net Debt = 3.67b EUR (calculated: Debt 4.18b - CCE 509.0m)
Enterprise Value = 12.5b EUR (8.80b + Debt 4.18b - CCE 509.0m)
Interest Coverage Ratio = 4.84 (Ebit TTM 763.0m / Interest Expense TTM 157.7m)
EV/FCF = 24.30x (Enterprise Value 12.5b / FCF TTM 513.1m)
FCF Yield = 4.12% (FCF TTM 513.1m / Enterprise Value 12.5b)
FCF Margin = 3.39% (FCF TTM 513.1m / Revenue TTM 15.2b)
Net Margin = 2.40% (Net Income TTM 364.3m / Revenue TTM 15.2b)
Gross Margin = 15.69% ((Revenue TTM 15.2b - Cost of Revenue TTM 12.8b) / Revenue TTM)
Gross Margin QoQ = 14.38% (prev 12.89%)
Tobins Q-Ratio = 1.07 (Enterprise Value 12.5b / Total Assets 11.7b)
Interest Expense / Debt = 3.77% (Interest Expense 157.7m / Debt 4.18b)
Taxrate = 39.95% (247.3m / 619.1m)
NOPAT = 458.2m (EBIT 763.0m * (1 - 39.95%))
Current Ratio = 1.70 (Total Current Assets 5.34b / Total Current Liabilities 3.14b)
Debt / Equity = 0.94 (Debt 4.18b / totalStockholderEquity, last quarter 4.43b)
Debt / EBITDA = 2.90 (Net Debt 3.67b / EBITDA 1.26b)
Debt / FCF = 7.15 (Net Debt 3.67b / FCF TTM 513.1m)
Total Stockholder Equity = 4.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.24% (Net Income 364.3m / Total Assets 11.7b)
RoE = 8.30% (Net Income TTM 364.3m / Total Stockholder Equity 4.39b)
RoCE = 10.92% (EBIT 763.0m / Capital Employed (Equity 4.39b + L.T.Debt 2.60b))
RoIC = 5.48% (NOPAT 458.2m / Invested Capital 8.36b)
WACC = 5.07% (E(8.80b)/V(13.0b) * Re(6.41%) + D(4.18b)/V(13.0b) * Rd(3.77%) * (1-Tc(0.40)))
Discount Rate = 6.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -4.61 | Cagr: -0.12%
[DCF] Terminal Value 73.55% ; FCFF base≈542.3m ; Y1≈487.4m ; Y5≈413.6m
[DCF] Fair Price = 20.28 (EV 6.60b - Net Debt 3.67b = Equity 2.93b / Shares 144.4m; r=8.35% [WACC [floored]]; 5y FCF grow -12.46% → 2.50% )
EPS Correlation: -82.93 | EPS CAGR: -26.37% | SUE: -0.10 | # QB: 0
Revenue Correlation: -92.22 | Revenue CAGR: -4.81% | SUE: 1.46 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.04 | Chg30d=+0.20% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=4.11 | Chg30d=+3.88% | Revisions=+67% | GrowthEPS=+83.4% | GrowthRev=+2.5%
EPS next Year (2027-12-31): EPS=4.18 | Chg30d=-0.33% | Revisions=+38% | GrowthEPS=+1.7% | GrowthRev=+0.1%
[Analyst] Revisions Ratio: +53% (up=10, down=2)